Numerosi sono i cani addestrati per persone disabili nel mondo, ma al momento in Italia l’unico cane riconosciuto e tutelato da una Legge dello Stato è il cane guida per persone disabili visive
Quando parliamo di persona con disabilità e cane che lo assiste, pensiamo automaticamente al cane guida per le persone cieche. In realtà esistono anche cani da assistenza per persone disabili non necessariamente cieche o ipovedenti, ma che abbiano disabilità di altro tipo. Sono cani addestrati allo scopo e che, ad esempio, ci aiutano a muoverci in casa aprendo per noi porte, accendendo e spegnendo luci, aiutandoci a vestirci.
Ma mentre il cane guida per persone disabili visive è riconosciuto e tutelato da una Legge dello Stato (dal 1974), in Italia tutti gli altri cani addestrati per varie disabilità ne sono privi. In Italia, attualmente, chi è accompagnato da un cane guida, grazie alla
Illinois is poised to become the 11th state in the U.S. to legalize marijuana for recreational use, after lawmakers voted to legalize the drug on Friday afternoon. The Illinois House passed HB 1438, 66-47, after it went through the Senate on Wednesday. The final hurdle will be sending the bill to Democratic Gov. J.B. Pritzker,…
“My name is Professor Finbar O’Callaghan and I am here as president of the British Paediatric Neurology Association which is the association which represents all paediatric neurologists in the UK. I’m also a consultant paediatric neurologist at Great Ormond Street, an epileptologist and professor of paediatric neuroscience at UCL. I have a particular interest in epidemiology and clinical trials and in particular running clinical trials in childhood epilepsy.”
It’s hardly surprising then that in such a pre-eminent position, his opinion on the use of medical cannabis in paediatric epilepsy is regarded as if it had the force of law amongst doctors. But I point you to his…
For more information, contact Paul Armentano, NORML Deputy Director, at: email@example.com. Full text of the study, “Are cannabis users likely to gain weight? Results from a national 3-year prospective study,” appears in the International Journal of Epidemiology
The announcement has not yielded anywhere near the level of access to cannabis that many were hoping for (or indeed, relying on) as since the November 1st announcement, the number of people who have actually accessed cannabis via prescription can be counted on one hand (and even then, only accessing via expensive private consultations).
Despite this, the cannabis scene has been thriving with numerous entrepreneurs, activists, academics, corporations and medical professionals getting involved with various projects to help push the industry forward.
One of the most interesting projects is Leafpost, a start-up who are committed to opening London’s…
A third of patients with Gp symptoms actively use cannabinoids for their chronic symptoms. Most of these patients perceive improvement in their symptoms with cannabinoids. Patients taking cannabinoids were younger and more symptomatic than those not taking cannabinoids. Further studies on the efficacy and safety of cannabinoids in Gp will be useful.
Geneva, Switzerland: Members of the World Health Organization (WHO) Expert Committee on Drug Dependence have proposed amending the classification of cannabis under international law.
According to reporting in the British Medical Journal, the WHO policy reversal “takes account of the growing evidence for the medical applications of the drug,” and marks the first time that the agency has reviewed its stance on cannabis in nearly 60 years.
The recommended changes, outlined in a letter by WHO Director-General Dr. Tedros Adhanom Ghebreyesus, call for cannabis to be removed from Schedule IV of the 1961 Single Convention on Narcotic Drugs. Schedule IV is the most restrictive classification under the treaty. Instead, the committee advises that whole-plant cannabis and THC be designated as Schedule I controlled substances under international law.
“The current [international] scheduling of cannabis is as strict as that for heroin,” the BMJ summarizes. “[T]he Committee believes that keeping cannabis at that level of control would severely restrict access to and research on potential therapies derived from the plant.”
In a separate recommendation, the Committee reiterated its 2017 request that preparations containing “pure cannabidiol … and not more than 0.2 percent of delta-9-tetrahydrocannabinol” no longer be scheduled within the international drug conventions.
The Committee’s policy recommendations now await action from the 53 participating members states of the United Nation’s Commission on Narcotic Drugs. The Commission is anticipated to vote on the issue in March.
In October, NORML delivered over 10,000 public comments to the US Food and Drug Administration urging the agency to recommend that WHO reschedule cannabis internationally.
For more information, contact Erik Altieri, NORML Executive Director, at (202) 483-5500.